Sigmoidoscope market seen topping $3.59 billion by 2030

The sigmoidoscope market reached $2.67 billion in 2025 and is projected to rise to $3.59 billion by 2030, driven by colorectal cancer screening demand, outpatient diagnostics and infection-control preferences. North America led in 2025, while Asia-Pacific is expected to grow fastest.

Why it matters: - Sigmoidoscopes are a frontline diagnostic tool for spotting colorectal abnormalities early, which can improve treatment outcomes and survival. - Rising colorectal cancer incidence is keeping demand for lower-intestine screening devices elevated across hospitals and outpatient settings. - The market’s growth reflects a broader shift toward disposable devices, advanced imaging and patient-safety-focused procedures.

What happened: - The sigmoidoscope market was valued at $2.67 billion in 2025. - The market is projected to reach $2.83 billion in 2026 and $3.59 billion by 2030. - The projected compound annual growth rate is 6.1% from 2025 to 2030. - The Business Research Company released the market update on Aug. 26, 2026. - The company also made a free sample report available and pointed readers to the full market report.

The details: - A sigmoidoscope is used to inspect the sigmoid colon and rectum. - The device is inserted through the anus into the lower large intestine. - Sigmoidoscopes can be flexible or rigid and include a light source plus a camera or lens system. - The instrument helps clinicians identify polyps, tumors, inflammation and other abnormalities. - Growth has been supported by rising colorectal disorders, wider use of endoscopic diagnostics, hospital endoscopy unit expansion and reusable sigmoidoscope technologies. - Future growth is expected to come from demand for disposable endoscopy devices, more outpatient diagnostic procedures, expanded colorectal screening programs and investment in advanced imaging. - Key trends include high-definition flexible sigmoidoscopes, single-use devices, integrated imaging systems, minimally invasive diagnostics and stronger infection-control standards. - In February 2025, the UK Office for National Statistics reported 15,552 colorectal cancer deaths registered in England and Wales in 2023.

Between the lines: - The market outlook suggests infection control is becoming a bigger buying factor, not just a clinical preference. - North America’s 2025 lead points to mature screening infrastructure, while Asia-Pacific’s faster growth suggests room for expanding access and diagnosis rates. - The mix of reusable and single-use products shows the market is balancing cost pressure against safety and sterility concerns.

What's next: - Market expansion is expected to continue through 2030 at the same 6.1% annual pace. - Buyers and providers are likely to focus more on outpatient workflows and device designs that support faster, safer procedures. - The company says its 2026 reports now include market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel dashboards, market hotspot infographics and updated trend analysis. - The Business Research Company is directing readers to contact Saumya Sahay for more information, with regional phone numbers and marketing@tbrc.info listed in the release.

The bottom line: - The sigmoidoscope market is growing steadily, and the strongest demand signals are coming from colorectal cancer screening, disposable-device adoption and patient-safety priorities.